Canaccord Genuity Reiterates a 'Buy' on Teva Pharma (TEVA); Win Now A Reality
Tweet Send to a FriendGet Alerts TEVA Hot Sheet
Price: $39.35 -2.14%
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Rating Summary:
7 Buy, 16 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 28 | New: 14
Trade TEVA Now!
Canaccord Genuity reiterates a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.
Analyst, Randall Stanicky, said, "Friday evening, the U.S. district court for the Southern District of New York ruled in favor of Teva’s patent infringement lawsuit against Momenta (Nasdaq: MNTA)/Sandoz and Mylan (NYSE: MYL)/Natco covering patents that extend to September of 2015. A decision had been imminent and keeping many on the sidelines given the magnitude of P&L risk (US Copaxone is ~ 34% of EPS based on our estimate). With a win now a reality and risk removed, the stock should see a boost with what we think will be solid follow-through into the H2 business review updates."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday, with a 52 week range of $35.00-$49.72.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Randall Stanicky, said, "Friday evening, the U.S. district court for the Southern District of New York ruled in favor of Teva’s patent infringement lawsuit against Momenta (Nasdaq: MNTA)/Sandoz and Mylan (NYSE: MYL)/Natco covering patents that extend to September of 2015. A decision had been imminent and keeping many on the sidelines given the magnitude of P&L risk (US Copaxone is ~ 34% of EPS based on our estimate). With a win now a reality and risk removed, the stock should see a boost with what we think will be solid follow-through into the H2 business review updates."
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $38.10 yesterday, with a 52 week range of $35.00-$49.72.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- KeyBank Upgrades MDC Holdings (MDC); Cuts PulteGroup (PHM) & Ryland Group (RYL)
- Wells Fargo Starts Popular, Inc. (BPOP) at Outperform
- Goldman Sachs Downgrades InterXion Holding (INXN) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, LitigationRelated Entities
Canaccord Genuity
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
